Business context and reporting period
The supplied filing is GlycoMimetics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2015—not a filing for Crescent BioPharma, Inc., as stated in the request metadata. GlycoMimetics is a clinical-stage biotechnology company with no approved products or product-sale revenue. Its pipeline includes rivipansel, licensed to Pfizer, and company-developed candidates GMI-1271 and GMI-1359.
Financial highlights
| Metric | Three months ended September 30, 2015 | Nine months ended September 30, 2015 |
|---|---|---|
| Revenue | $0 | $20.0 million |
| Research and development expense | $5.0 million | $18.1 million |
| General and administrative expense | $2.1 million | $5.8 million |
| Net loss | $7.2 million | $3.9 million |
| Net loss per share | $0.38 | $0.20 |
- Nine-month revenue was primarily the $20.0 million Pfizer milestone triggered by first-patient dosing in rivipansel’s Phase 3 trial; it is milestone revenue, not recurring product sales. The filing reports no third-quarter revenue.
- Cash and cash equivalents were $53.8 million at September 30, 2015, down $1.4 million from year-end 2014. Nine-month operating cash use was $1.3 million; investing cash use was $0.3 million, and financing provided $0.1 million.
- Current assets were $54.5 million and current liabilities $6.9 million. Total liabilities were $7.0 million; the balance sheet lists no debt.
- Gross margin is not meaningful for this development-stage business: the filing reports no product sales or cost of product revenue.
Changes versus the prior comparable period
- For the first nine months, revenue rose from $15.0 million to $20.0 million, reflecting Pfizer milestone payments in each period. Net loss increased from $3.7 million to $3.9 million.
- Nine-month R&D expense increased 27% to $18.1 million, primarily due to GMI-1271 manufacturing and clinical-trial preparation, GMI-1359 preclinical work, increased staffing, and a $2.0 million University of Basel milestone-related fee.
- Nine-month G&A expense increased 30% to $5.8 million, mainly from professional fees and stock-based compensation.
- Cash was $53.8 million versus $55.2 million at December 31, 2014. The prior-year nine-month cash flows included $57.2 million of IPO proceeds; 2015 financing cash flow did not.
Outlook, risks and notable items
- Management expected existing cash to fund operations through the first quarter of 2017 in the Outlook section, but elsewhere stated it expected funding through the fourth quarter of 2016. This runway estimate is inconsistent within the filing.
- The company expects losses and negative operating cash flows to continue, with R&D spending likely to rise. It may need additional equity, debt, or collaboration financing; additional capital may be unavailable or may dilute shareholders or require concessions.
- Pfizer controls further development and commercialization of rivipansel. Potential future milestones and royalties are contingent and uncertain; the company retained rights to its other candidates.
- Key risks include clinical-trial enrollment and results, regulatory approval, manufacturing, intellectual-property protection, and the ability to secure financing. The filing says risk factors had not materially changed from the 2014 Form 10-K.
- Management reported effective disclosure controls as of September 30, 2015, and no material change in internal control over financial reporting. No material legal proceedings were reported.
Investor facts to verify
- Confirm the issuer: the supplied text identifies GlycoMimetics, Inc., not Crescent BioPharma, Inc.
- Reconcile the stated cash runway through Q4 2016 versus Q1 2017 and review the assumptions behind each estimate.
- Verify the timing of the $20.0 million Pfizer milestone: the filing says it was triggered and recognized in June 2015, while other text refers to receipt in August 2015.
- Track GMI-1271 trial progress and spending, and Pfizer’s rivipansel Phase 3 progress and any remaining contingent milestone opportunities.
- Assess future financing needs, dilution risk, and the company’s cash use as development programs advance.